Over the past 20 years, significant advancements in stem cell research and therapies have been one of the most promising methods of creating new insulin making cells needed to cure type 1 diabetes.

Vertex Pharmaceuticals, a biotech company, recently began a clinical trial where it plans to treat 17 participants who have type 1 diabetes with new stem cell derived insulin making cells. The first patient in the trial has had positive results.

Other companies around the world including ViaCyte and CRISPR, as well as Novo Nordisk, one of the biggest insulin manufacturers in the world, are also working on curing the disease. CNBC explores why finding a cure for diabetes is so hard and just how close Vertex and other companies are to solving this problem.

» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic

About CNBC: From ‘Wall Street’ to ‘Main Street’ to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.

Connect with CNBC News Online
Get the latest news: https://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC

#CNBC

How There Could Finally Be A Cure For Diabetes

Share on

Share on